États-Unis · Plateformes & données · Yahoo Finance

Is Krystal Biotech (KRYS) Undervalued On Earnings, Buybacks, And Vyjuvek Growth?

Publié par Yahoo Finance · États-Unis il y a 13 h

Krystal Biotech (KRYS) just paired a third quarter earnings beat with a new US$400 million share repurchase plan, giving investors fresh numbers on Vyjuvek demand and updated…

Lire l'article complet sur Yahoo Finance Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finance.yahoo.com)

Is Krystal Biotech (KRYS) Undervalued On Earnings, Buybacks, And Vyjuvek Growth?

À lire aussi

Fabrinet (FN) Q1 2027 Earnings Call Transcript

Angel Oak Financial Strategies Income Term declares $0.115 dividend

Adani Group seeks $1.5 bln loan for data center expansion- Economic Times

Stock market after midterm elections: What S&P 500 history shows

Theta Gold Mines Reports Expiry of 12.6 Million Options

Amundi Funds - Income Opportunities A70 SGD MTD2 D

Is Krystal Biotech (KRYS) Undervalued On Earnings, Buybacks, And Vyjuvek Growth?

Partager

À lire aussi

Fabrinet (FN) Q1 2027 Earnings Call Transcript

Angel Oak Financial Strategies Income Term declares $0.115 dividend

Adani Group seeks $1.5 bln loan for data center expansion- Economic Times

Stock market after midterm elections: What S&P 500 history shows

Theta Gold Mines Reports Expiry of 12.6 Million Options

Amundi Funds - Income Opportunities A70 SGD MTD2 D